Reduced T-cell response following a third dose of SARS-CoV-2 vaccine in infection-naïve people living with HIVArticle Published on 2022-12-012023-07-10 Journal: The Journal of Infection [Category] COVID19(2023년), [키워드] Antibody responses Breakthrough infection cellular COVID-19 vaccine HIV humoral immune response neutralisation omicron people living with HIV SARS-CoV-2 mRNA vaccine third dose. [DOI] 10.1016/j.jinf.2022.09.006 PMC 바로가기
Pausing methotrexate prevents impairment of Omicron BA.1 and BA.2 neutralisation after COVID-19 booster vaccinationArticle Published on 2022-10-012022-11-16 Journal: RMD Open [Category] COVID19(2023년), SARS, 변종, [키워드] administration Arthritis booster booster vaccination control group COVID-19 COVID-19 vaccination demonstrated Epidemiology impairment medication methotrexate mRNA MTX neutralisation neutralising Observational cohort study occur omicron Patient Prevent pseudovirus neutralisation assay reached receiving SARS-CoV-2 serum significantly higher significantly lower therapy Treatment vaccination vaccination. vaccine response variant variants were assessed while wild-type [DOI] 10.1136/rmdopen-2022-002639 PMC 바로가기
SARS-CoV-2 Omicron BA.5: Evolving tropism and evasion of potent humoral responses and resistance to clinical immunotherapeutics relative to viral variants of concernArticle Published on 2022-09-182022-10-06 Journal: EBioMedicine [Category] COVID19(2023년), SARS, 변종, 진단, 치료제, [키워드] absence ACE2 acute respiratory syndrome ADK antibody BA.2 BA.5 Beta BNT162b2 breadth Breakthrough infection cell line change circulating clade Clinical effect cohorts contributed convalescent convalescent sera coronavirus COVID-19 COVID-19 hospitalisation Delta development disease severity Donor donors dose foundation Future genetic difference greater humoral Humoral response IgG in vitro isolate Lineage lineages Live virus management monitoring monoclonal antibody mortality rates nafamostat nasopharyngeal sample nasopharyngeal swabs neutralisation neutralisation assay Neutralising Antibodies neutralising antibody New observation of BNT162b2 omicron Omicron BA.1 other variant pathway peak plasma potency recorded reduced reduction reduction in Research response responses SARS-CoV-2 sensitivity significantly Sotrovimab South Spread Support supported tested Testing therapeutic Therapies TMPRSS2 TMPRSS2 inhibitor TMPRSS2. Transmission utilised vaccination Vaccine variant viral lineage viral variant [DOI] 10.1016/j.ebiom.2022.104270 PMC 바로가기 [Article Type] Article
Rapamycin and inulin for booster vaccine response stimulation (RIVASTIM)-rapamycin: study protocol for a randomised, controlled trial of immunosuppression modification with rapamycin to improve SARS-CoV-2 vaccine response in kidney transplant recipientsArticle Published on 2022-09-152022-11-15 Journal: Trials [Category] SARS, 진단, [키워드] 1:1 binding domain Booster vaccine cell-mediated response clinical Controlled trial COVID COVID-19 COVID-19 vaccination COVID-19 vaccine death develop disease severity dose Effectiveness Efficacy ENhance hospitalisation humoral hypothesise IgG immune cell population immunological Immunosuppression IMPROVE include increased risk Intervention kidney transplant recipient kidney transplant recipients Kidney transplantation live SARS-CoV-2 Modification mTOR inhibitor multicentre neutralisation New outcome participant Prednisolone Primary outcome proportion Protective protective immunity public health randomised randomised controlled trial Rapamycin recipient reduce reduced regimen registry responses SARS-CoV-2 SARS-CoV-2 vaccine secondary serological Sirolimus Standard of care Study protocol Tolerability Trial vaccination vaccination. Vaccine vaccine response virus [DOI] 10.1186/s13063-022-06634-w PMC 바로가기
COVID-19 Adaptive Humoral Immunity Models: Weakly Neutralizing Versus Antibody-Disease Enhancement ScenariosCOVID-19 적응 체액 면역 모델: 약한 중화 대 항체 질병 강화 시나리오Article Published on 2022-08-132022-09-12 Journal: Acta biotheoretica [Category] SARS, 진단, [키워드] ADE Antibody disease enhancement Antibody-dependent enhancement approach COVID-19 disease Disease progression Effect enhancement Final immune immune response immune system implication infected cell neutralisation neutralising antibody Non-neutralizing antibodies proportion SARS-CoV-2 scenario Secondary infection vaccination viral clearance viral dynamics virus Virus - immune system interaction Virus model. [DOI] 10.1007/s10441-022-09447-1 PMC 바로가기 [Article Type] Article
Skin-patch delivered subunit vaccine induces broadly neutralising antibodies against SARS-CoV-2 variants of concern피부 패치 전달 소단위 백신은 우려되는 SARS-CoV-2 변이체에 대한 광범위 중화 항체 유도Article Published on 2022-08-122022-09-11 Journal: Vaccine [Category] COVID19(2023년), MERS, SARS, 변종, 진단, [키워드] booster circulation COVID-19 Delta demonstrated dominant Efficacy Health high-density highlight Immunity immunized induce mice Microarray Microarray patch Mutation neutralisation Neutralising Antibodies neutralising antibody omicron Omicron variant resulting robust SARS-CoV-2 SARS-CoV-2 pandemic SARS-CoV-2 variant serum Spike protein subunit Subunit vaccine tested the spike protein Vaccine vaccine. variant variants variants of concern Viral viral strain Viral variants [DOI] 10.1016/j.vaccine.2022.07.013 PMC 바로가기 [Article Type] Article
Structural basis of Omicron immune evasion: A comparative computational study오미크론 면역 회피의 구조적 기반: 비교 전산 연구Article Published on 2022-08-012022-09-11 Journal: Computers in biology and medicine [Category] COVID19(2023년), SARS, 변종, [키워드] ACE2 Affect analysis angiotensin antibody binding affinities binding affinity Compromised Compromised neutralisation Critical Delta develop effective Effectiveness Efficacy evaluated explain immune Immune escape immune evasion immunogenic interact Interaction interface mapped molecular docking molecular dynamics Molecular dynamics simulation molecular dynamics simulations Mutation neutralisation Neutralising Antibodies neutralising antibody new strain omicron Omicron variant Protein RBD Receptor binding domain receptors reported robust S protein SARS-CoV-2 SARS-CoV-2 variants SARS-CoV-2 variants. several variants Spike protein the antibody the binding affinity the spike protein Vaccine Vaccine design variant variants variants of concern virus [DOI] 10.1016/j.compbiomed.2022.105758 PMC 바로가기 [Article Type] Article
Limited neutralisation of the SARS-CoV-2 Omicron subvariants BA.1 and BA.2 by convalescent and vaccine serum and monoclonal antibodies회복기 및 백신 혈청 및 단일 클론 항체에 의한 SARS-CoV-2 오미크론 하위 변이체 BA.1 및 BA.2의 제한된 중화Article Published on 2022-08-012022-09-11 Journal: EBioMedicine [Category] COVID19(2023년), MERS, SARS, 변종, 진단, [키워드] ACE2 addition antibody BA.1 BA.2 BNT162b2 booster booster dose booster vaccination breakthrough infections Casirivimab Cell Complete convalescent convalescent sera Delta dominant dose education Efficacy elicited exhibited expressing Frankfurt Imdevimab Immunity in vitro study individual infection with SARS-CoV-2 Limited majority median monoclonal antibodies monoclonal antibody monoclonal antibody therapy Mutation neutralisation neutralise neutralising neutralizing capacity omicron Omicron variants reduced Region SARS-CoV-2 sera serum Sotrovimab specific resistance Spike protein supported tested the SARS-CoV-2 the spike protein therapy TMPRSS2 university vaccination Vaccine Vaccines variants variants of SARS-CoV-2 waning immunity Waning Immunity. [DOI] 10.1016/j.ebiom.2022.104158 PMC 바로가기 [Article Type] Article
Safety and immunogenicity of intramuscular, single-dose V590 (rVSV-SARS-CoV-2 Vaccine) in healthy adults: Results from a phase 1 randomised, double-blind, placebo-controlled, dose-ranging trial건강한 성인을 대상으로 한 단일 용량 V590(rVSV-SARS-CoV-2 Vaccine)의 근육 내 안전성 및 면역원성: 1상 무작위 배정, 이중 맹검, 위약 대조, 용량 범위 시험 결과Clinical Trial Published on 2022-08-012022-09-11 Journal: EBioMedicine [Category] COVID19(2023년), MERS, SARS, 임상, 진단, 치료법, [키워드] Administered administration Adults adverse event adverse events AEs anti-SARS-CoV-2 Antibody responses comparable COVID-19 COVID-19 vaccine Day dose double-blind Endpoint fatigue global pandemic headache healthy highest dose immunogenicity Inc. Injection-site pain intramuscular lower dose neutralisation neutralising antibody response Older overcome Part participant pfu Phase 1 phase 1 study Placebo placebo-controlled plaque plaque-forming unit plaque-forming units primary endpoints PRNT50 randomised receive reduction Registration reported Result Safety SARS-CoV-2 SARS-CoV-2 nucleocapsid seronegative seronegative participant seronegative participants seropositive serum Sharp spike-specific antibody response stomatitis subsidiary Trial USA V590 Vaccine vesicular stomatitis vesicular stomatitis virus Vesicular stomatitis virus (VSV). virus VSV [DOI] 10.1016/j.ebiom.2022.104138 PMC 바로가기 [Article Type] Clinical Trial
Mutational induction in SARS-CoV-2 major lineages by experimental exposure to neutralising sera중화 혈청에 대한 실험적 노출에 의한 SARS-CoV-2 주요 계통의 돌연변이 유도Article Published on 2022-07-212022-09-11 Journal: Scientific Reports [Category] COVID19(2023년), MERS, SARS, 변종, 유전자 메커니즘, 진단, [키워드] acquisition addition antibody characterisation escape mutation Evolution Evolution of SARS-CoV-2 human population immune evasion immune response Interaction Lineage Mutagenesis neutralisation neutralising neutralising antibody Neutralizing antibody response offer Perspective promoted required responsible SARS-CoV-2 sera species structural protein structural proteins target Viral viral adaptation viral variant [DOI] 10.1038/s41598-022-16533-4 PMC 바로가기 [Article Type] Article